Skip to main content

Table 1 Baseline patient characteristics and treatment

From: Potency preservation following stereotactic body radiation therapy for prostate cancer

Patients (n = 97)
Age (years) Age ≤ 60 14 (14.4%)
  60 < Age ≤ 70 55 (56.7%)
  Age > 70 28 (28.9%)
Race   
  White 47 (48.5%)
  Black 46 (47.4%)
  Other 4 (4.1%)
Median Pre- Tx PSA (ng/ mL) Median   5.9 (1.8-32.5)ng/mL
Median Pre- Tx testosterone (nmol/ L)   11.4 (4.4-27.9)nmol/L
Partner status   
  Partnered 73 (75.3%)
  Not partnered 24 (24.7%)
Charlson comorbidity index (CCI)   
  0 78 (80.4%)
  1 13 (13.4%)
  2 5 (5.2%)
  3 1 (1%)
Body mass index (BMI)   
  <25 24 (24.7%)
  25-29.99 46 (47.4%)
  30-34.99 23 (23.7%)
  ≥ 35 4 (4.1%)
Risk group (D’ Amico’ s)   
  Low risk 43 (44.3%)
  Intermediate risk 50 (51.5%)
  High risk 4 (4.1%)
Work status   
  Working 57 (58.8%)
  Non-working 40 ((41.2%)
Pre-treatment SHIM score   
  22-25 (No ED) 49 (50.5%)
  17-21 (Mild ED) 32 (33.0%)
  12-16 (Mild Moderate ED) 10 (10.3%)
  8-11 (Moderate ED) 2 (2.1%)
  < 8 (Severe ED) *(No Sexual Activity) 4 (4.1%)
Sexual aid   
  None 62 (63.9%)
  Oral 35 (36.1%)
  Vacuum 1 (1.0%)
  Suppository/injection 0 (0%)
Dose (Gy)   
  36.25 87 (89.7%)
  35 9 (9.3%)
  Other 1 (1.0%)